Jun-Seok Lee
banner
junseoklee.bsky.social
Jun-Seok Lee
@junseoklee.bsky.social
It is interesting phenomena that Korean Ginseng has contradicting effect depending on the host cells.
My PhD student, Yevheniia, did hard work to finish this interesting project. If you work on Avian Influenza study, please check this out.

x.com/kumcnews/sta...

doi.org/10.1016/j.ph...
KOREA UNIVERSITY MEDICINE(고려대학교의료원) on X: "🧪Korean Red Ginseng extract (RGE) fights H9N2 flu 🦠but may boost H1N1 in some lung cells 🔄Cell-type matters: effects vary by virus & treatment mode 🎯 Potential for targeted antiviral use. 🔗 https://t.co/XrNpJM54Rs #Ginseng #Influenza #Antiviral #PrecisionMedicine #Virology" / X
🧪Korean Red Ginseng extract (RGE) fights H9N2 flu 🦠but may boost H1N1 in some lung cells 🔄Cell-type matters: effects vary by virus & treatment mode 🎯 Potential for targeted antiviral use. 🔗 https://t.co/XrNpJM54Rs #Ginseng #Influenza #Antiviral #PrecisionMedicine #Virology
x.com
July 14, 2025 at 11:40 AM
It is really happy news that my graduate student, Kostiantyn, from Korea University College of Medicine received the best POSTER award from 20th Asian Chemical Congress at Bangkok, Thailand. Huge congrats!

#chembio #KoreaUniversityCollegeOfMedicine
#AsianChemicalCongress #Bangkok
June 26, 2025 at 12:30 PM
Do you have bioactive compounds/drug molecules and want to unveil the mode of action? Chemoproteomic profiling is a promising solution to reveal the interaction partners in the cells, so to get a sense of how it works.
May 19, 2025 at 9:37 AM
I’m thrilled to announce the launch of the Drug Target Discovery Institute on April 28 at Korea University College of Medicine!
Check out the opening symposium poster & join us for an inspiring symposium featuring three world-renowned keynote speakers:
April 15, 2025 at 6:59 AM
Happy to be in Osaka again & participating 2025 annual meetings in Chemistry Society of Japan (CSJ).
What a beautiful Kansai University campus.
I am honored to be invited for a Keynote lecture in Asian International Symposium. Learned a lot from this fantastic session.
April 8, 2025 at 12:13 PM
Reposted by Jun-Seok Lee
March 27 (Thu), 13:00–15:40
Speakers: Yukihiro Itoh (Osaka Univ.), @junseoklee.bsky.social sky.social (Korea Univ.), Haruo Aikawa (Univ. of Tokyo), Gong Chen (Nankai Univ.), Minami Odagi (Tokyo Univ. Agri.), Tuoping Luo (Peking Univ.)
pub.confit.atlas.jp/en/event/csj...
[[A]D302-2pm] Asian International Symposium - Natural Products Chemistry, Chemical Biology / Biofunctional Chemistry and Biotechnology / Medicinal Chemistry - | The 105th CSJ Annual Meeting | Confit
Thu. Mar 27, 2025 1:00 PM - 3:40 PM JST The 105th CSJ Annual Meeting
pub.confit.atlas.jp
February 14, 2025 at 6:53 AM
The first photoswitchable photosensitizers for cancer photodynamic therapy (PDT). While light-controlled drug has been extensively studied, PDT agents have remained unexplored as a photopharmacological modality.
Dyad System of BOAHY-BODIPY Conjugates as Novel Photoswitchable Photosensitizers for Photodynamic Therapy
Photodynamic therapy (PDT) offers minimally invasive and repeatable cancer treatment options. Despite advancements in photosensitizer (PS) design, the optical control of PS activation remains unexplor...
doi.org
February 1, 2025 at 4:32 AM
Dis-/aggregation-dependent chemosensing is well-studied, but quantitative insights into supramolecular aggregation remain scarce. Our study introduces a straightforward approach: DC₅₀ plotted against solvent polarity parameters, offering valuable insights for chemosensor design. #AIE
t.co/nU7axereRA
https://onlinelibrary.wiley.com/doi/10.1002/bkcs.12933
t.co
January 19, 2025 at 7:15 AM
If you are interested in TPD tech but worried about synthesis of the compound, you can still design your own TPD agent using Aptamer and N-Degron Ensemble (AptaGron) platform. Check out our strategy from our latest study.

pubs.acs.org/doi/10.1021/...

#KoreaUniversity #PROTAC #TPD
Aptamer and N-Degron Ensemble (AptaGron) as a Target Protein Degradation Strategy
Target protein degradation (TPD) is a promising strategy for catalytic downregulation of target proteins through various cellular proteolytic pathways. Despite numerous reports on novel TPD mechanisms, the discovery of target-specific ligands remains a major challenge. Unlike small-molecule ligands, aptamers offer significant advantages, owing to their SELEX-based systematic screening method. To fully utilize aptamers for TPD, we designed an aptamer and N-degron ensemble system (AptaGron) that circumvents the need for synthetic conjugations between aptamers and proteolysis-recruiting units. In our AptaGron system, a peptide nucleic acid containing an N-degron peptide and a sequence complementary to the aptamer was designed. Using this system, we successfully degraded three target proteins, tau, nucleolin, and eukaryotic initiation factor 4E (eIF4E), which lack specific small-molecule ligands. Our results highlight the potential of the AptaGron approach as a robust platform for targeted protein degradation.
pubs.acs.org
December 22, 2024 at 4:23 AM